University Clinical Research - Deland, LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$32,045	5
2024	Research	$31,800	2
2022	Research	$20,469	9

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $60,345 5 payments
Philips Electronics North America Corporation $12,000 4 payments
Alnylam Pharmaceuticals Inc. $10,719 6 payments
Celgene Corporation $1,250 1 payment

Studies the money was for Research payments · program years 2022–2025

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $26,895 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) $21,500 1 payment
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $11,950 2 payments
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) $10,719 6 payments
Iguideu Study $9,750 3 payments
Monitoring Visit, Close out Visit $2,250 1 payment
A Phase 3B, Multicenter, Open-Label Study to Evaluate the Immunological Response To, and the Safety Of, Three Parenterally Administered Vaccines in Subjects With Relapsing Remitting Multiple Sclerosis Who Receive Oral Ozanimod, Non-Pegylated Interferon-, Or No Disease Modifying Therapy $1,250 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.